Streetbeat News

Products Services

VRAX

Virax Biolabs has announced a distribution agreement to commercialize its Mpox Virus RT-PCR detection kits in Europe and the Middle East. This move could expand the company's market reach and potentially increase its revenue.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 11:15 am

MRUS

Foundation Medicine and Merus N.V. have announced a collaboration to develop an RNA platform as a companion diagnostic for Merus's bispecific antibody zenocutuzumab (Zeno) to treat neuregulin 1 fusion cancers.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 11:13 am

KRYS

Jeune Aesthetics, a subsidiary of Krystal Biotech, announced positive interim results from the PEARL-1 Phase 1 study evaluating KB301 for treating lateral canthal lines and dynamic wrinkles of the décolleté. This development could positively impact Krystal Biotech's stock.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 11:11 am

NVDA

SOX

Nvidia is set to announce its Q2 results, with analysts expecting strong growth driven by AI demand. Concerns over a potential delay in the Blackwell AI accelerator are present, but analysts remain optimistic about Nvidia's leadership in AI and accelerated computing.

Portfolio Pulse from Shanthi Rexaline

August 28, 2024 | 11:09 am

NBIX

Neurocrine Biosciences announced positive top-line results from its Phase 2 clinical study of NBI-1117568, a treatment for adults with schizophrenia. This development could impact the company's stock positively.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 11:09 am

FFIV

INTC

F5 has partnered with Intel to enhance application security and delivery for AI deployments. The collaboration integrates F5's NGINX Plus with Intel's OpenVINO toolkit and IPUs, aiming to improve protection, scalability, and performance for AI inference.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 11:07 am

AVIR

Atea Pharmaceuticals published new data on the metabolic activation pathway of bemnifosbuvir, an antiviral in development for COVID-19 and HCV treatment.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 11:07 am

NRSN

NeuroSense Therapeutics is in advanced discussions with several major pharmaceutical companies for a strategic partnership to develop and commercialize its lead drug candidate, PrimeC, for ALS treatment.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 11:02 am

NRSN

NeuroSense Therapeutics is in advanced talks with several large pharmaceutical companies for a strategic partnership to develop and commercialize its lead drug, PrimeC, for ALS. The discussions could lead to significant financial benefits for NeuroSense, though no definitive agreement has been reached yet.

Portfolio Pulse from Vandana Singh

August 28, 2024 | 11:00 am

NVS

Novartis Pharma AG, a subsidiary of Novartis, has entered into a global licensing agreement and strategic collaboration with Lindy Biosciences to innovate in multi-target drug delivery.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 11:00 am